Sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists, and the risk of macrovascular, and microvascular complications among patients with type 2 diabetes and non-alcoholic fatty liver disease

被引：0
|
作者：
Bea, Sungho [1 ]
Filion, Kristian B. [2 ]
Shin, Ju-Young [1 ]
机构：
[1] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea
[2] McGill Univ, Montreal, PQ, Canada
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
58
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [1] Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes
    Pradhan, Richeek
    Yin, Hui
    Yu, Oriana
    Azoulay, Laurent
    DIABETES CARE, 2022, 45 (04) : 819 - 829
  • [2] Prescription of Sodium-glucose cotransporter-2 inhibitors and Glucagon-like peptide-1 receptor agonists among Veterans with diabetes and cardiovascular disease
    Qaisrani, Fatima
    Wu, Jingyi
    Eberly, Lauren
    Khatana, Sameed Ahmed
    CIRCULATION, 2024, 150
  • [3] COMPARING ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS OR SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS
    Damachi, U.
    Enobun, B.
    Onukwugha, E.
    Cooke, C. E.
    Slejko, J. F.
    VALUE IN HEALTH, 2023, 26 (06) : S321 - S322
  • [4] Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
    Mantovani, Alessandro
    Byrne, Christopher D.
    Targher, Giovanni
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (04): : 367 - 378
  • [5] Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
    Lin, Tzu-Yi
    Kang, Eugene Yu-Chuan
    Shao, Shih-Chieh
    Lai, Edward Chia-Cheng
    Garg, Sunir J.
    Chen, Kuan-Jen
    Kang, Je-Ho
    Wu, Wei-Chi
    Lai, Chi-Chun
    Hwang, Yih-Shiou
    DIABETES & METABOLISM JOURNAL, 2023, 47 (03) : 394 - 404
  • [6] Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients
    Zheng, Katina
    Azhie, Amirhossein
    You, Xiaoting
    Naghibzadeh, Maryam
    Tan, Eunice
    Naimimohasses, Sara
    Sridhar, Vikas S.
    Gupta, Sarang
    Chen, Shiyi
    Dash, Satya
    Tsien, Cynthia
    Selzner, Nazia
    Lilly, Leslie
    Jaeckel, Elmar
    Woo, Minna
    Singh, Sunita
    Cherney, David
    Bhat, Mamatha
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4261 - 4272
  • [7] First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
    Carriazo, Soln
    Ortiz, Alberto
    Fernandez-Fernandez, Beatriz
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (04) : eL230007
  • [8] Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes
    Al-Ozairi, Ebaa
    Irshad, Mohammad
    Taghadom, Etab
    Sojan, Litty
    Al Kandari, Jumana
    Alroudhan, Dherar
    le Roux, Carel W.
    OBESITY, 2023, 31 (03) : 716 - 723
  • [9] Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors benefits add up?
    Karakasis, Paschalis
    Patoulias, Dimitrios
    Fragakis, Nikolaos
    Bernal-Lopez, Maria Rosa
    Gomez-Huelgas, Ricardo
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 130 : 155 - 159
  • [10] Patients' Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
    Banjara, Bidur
    Poudel, Nabin
    Garza, Kimberly B.
    Westrick, Salisa
    Whitley, Heather P.
    Redden, David
    Ngorsuraches, Surachat
    PATIENT PREFERENCE AND ADHERENCE, 2022, 16 : 3415 - 3428
12345